PLoS ONE (Jan 2012)

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

  • Reuben Granich,
  • James G Kahn,
  • Rod Bennett,
  • Charles B Holmes,
  • Navneet Garg,
  • Celicia Serenata,
  • Miriam Lewis Sabin,
  • Carla Makhlouf-Obermeyer,
  • Christina De Filippo Mack,
  • Phoebe Williams,
  • Louisa Jones,
  • Caoimhe Smyth,
  • Kerry A Kutch,
  • Lo Ying-Ru,
  • Marco Vitoria,
  • Yves Souteyrand,
  • Siobhan Crowley,
  • Eline L Korenromp,
  • Brian G Williams

DOI
https://doi.org/10.1371/journal.pone.0030216
Journal volume & issue
Vol. 7, no. 2
p. e30216

Abstract

Read online

BackgroundAntiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.MethodsWe model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count ResultsExpanding ART to CD4 count ConclusionIncreasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.